Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.08B 11.13B 10.45B 19.62B 1,326B 19.82B 131B 51.22B 649B 52.62B 51.5B 2,250B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.24B 10.35B 9.71B 18.24B 1,233B 18.43B 122B 47.63B 604B 48.93B 47.89B 2,092B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
02/04/25Issuer saleCompany 10,000 0.0094%
02/04/25Issuer sale

Director

52,606 0.0495%
02/04/25Issuer sale

Director

142,379 0.1339%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+106.21% 14.02B
-0.04%-0.24%+17.61%-21.50% 62.54B
-0.12%-5.52%+57.95%+196.67% 55.22B
+0.08%+33.30%+33.30%+33.30% 40.9B
+0.51%+3.73%-55.37%-62.46% 35.99B
-1.53%-1.75%+49.28%-34.24% 28.88B
+6.27%+16.07%+113.08%-56.96% 21.98B
-2.19%-3.37%+40.06%+57.76% 19.93B
-2.03%+0.67%-2.92%+110.25% 16.95B
+1.77%+0.83%+56.31%+101.19% 15.87B
Average -0.25%+1.87%+30.93%+43.02% 31.23B
Weighted average by Cap. -0.18%+1.19%+29.53%+40.04%

Financials

2023 2024
Net sales 464M 400M 369M 346M 650M 43.9B 656M 4.35B 1.7B 21.5B 1.74B 1.71B 74.51B 681M 587M 540M 507M 952M 64.37B 963M 6.38B 2.49B 31.52B 2.56B 2.5B 109B
Net income -140M -120M -111M -104M -195M -13.21B -197M -1.31B -510M -6.47B -524M -513M -22.41B -74.68M -64.36M -59.26M -55.64M -104M -7.06B -106M -700M -273M -3.46B -280M -274M -11.98B
Net Debt -481M -415M -382M -358M -673M -45.48B -680M -4.51B -1.76B -22.27B -1.81B -1.77B -77.18B -984M -848M -781M -733M -1.38B -93.04B -1.39B -9.23B -3.6B -45.56B -3.69B -3.61B -158B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!